FAQs - Frequently Asked Questions
about Diasorin

Simplexa^® Directassays are real-time PCR tests designed to deliver rapid, sample-to-answer results with streamlined workflows.

Simplexa^® Direct assays such as Simplexa^® COVID-19 / Flu A/B & RSV Direct allow laboratories to test directly from clinical specimens in a sample format without a separate nucleic-acid extraction step.

This “direct” approach reduces hands-on time and enables faster turnaround for critical infectious-disease targets, supporting rapid decision-making in hospital and lab settings. The expansive and highly differentiated menu includes claims exclusive to Diasorin.

Diasorin offers several solutions that support respiratory syndromic testing.

LIAISON PLEX^® Respiratory Flex Assay offers customizable syndromic testing, allowing labs to report only what’s necessary, and expand results without retesting based on seasonality and patient need.

Simplexa^®COVID-19 / Flu A/B & RSV Direct and other Simplexa^® respiratory assays provide rapid molecular detection of key seasonal respiratory viruses directly from clinical specimens.

LIAISON NES^® offers two assays: one for simultaneous detection of COVID, Flu A/B and RSV and one for the precise detection of group A strep, aimed at rapid testing in near-patient settings.

NxTAG^® Respiratory Pathogen Panel (RPP) v² and NxTAG^® RPP + SARS-CoV-2 broaden coverage to multiple respiratory viruses and bacteria—including influenza A/B, RSV and SARS-CoV-2—in a single syndromic panel.

Together, these solutions allow labs to tailor respiratory testing from high-throughput panels to rapid targeted assays.

Diasorin provides a full range of diagnostic kits and reagents including:

• CLIA immunoassays for infectious diseases, endocrinology, metabolism and gastrointestinal disorders (LIAISON^® XL and LIAISON^® XS).
• Targeted PCR-based assays such as Simplexa^® C. auris Direct and other targeted infectious disease assays as well as Primer Pairs (ASRs)
• Syndromic multiplex panels through LIAISON PLEX^® and NxTAG^® technologies (Respiratory, GI, Bloodstream).
• Point-of-care assays on the LIAISON NES^® system (Respiratory)

These products are listed across the assay pages in each product family on the US Diasorin website.

NxTAG^® assays are used for syndromic panel testing, where multiple pathogens are detected from a single sample.

• The NxTAG^® Respiratory Pathogen Panel (RPP) v2 combines multiple viral and bacterial respiratory targets in one assay, enabling laboratories to evaluate a broad set of pathogens when patients present with respiratory symptoms.

This syndromic solution help clinicians interpret complex respiratory clinical presentations more efficiently.

Diasorin offers a portfolio of platforms that cover immunodiagnostics and molecular diagnostics for clinical laboratories.

The LIAISON^® family of analyzers (LIAISON^® XL and LIAISON^® XS) provides fully automated CLIA immunoassay testing across specialties such as infectious diseases, gastrointestinal diseases, and metabolic disorders.

In molecular diagnostics, Diasorin provides LIAISON NES^® for point-of-care,Simplexa^® Direct for specialty targeted tests, as well as LIAISON PLEX^® and NxTAG^® assays for panel-based syndromic testing.

The LIAISON^® platform is Diasorin’s family of fully automated chemiluminescent immunoassay (CLIA) analyzers designed for medium- to high-throughput clinical laboratories.

The LIAISON^® XL and LIAISON^® XS share the same CLIA technology, allowing labs to scale capacity while maintaining consistent results.

LIAISON^® systems support a broad range of clinical applications, including:

• Metabolic disorders and Vitamin D testing (e.g., LIAISON^® Vitamin D Diagnostic Solution).
• Infectious diseases, with assays such as LIAISON^® QuantiFERON^® TB-Gold PlusII and a wide menu of viral and bacterial tests.
• Gastrointestinal diseases, including the LIAISON^® Calprotectin assay for inflammatory bowel disease (IBD).
• Hepatitis, HIV, and other viral serology including the LIAISON^® XL Murex HIV Ab/Ag HT and a full hepatitis menu.

You can use the LIAISON^® Family Menu and specialty pages on the website to explore the full test offering.

Diasorin’s portfolio is structured so that different platforms address distinct workflow and throughput needs.

• LIAISON^® XL is a fully automated platform suited for high-throughput hospital and link laboratories, offering a broad CLIA menu and high productivity for routine and specialty testing.
• LIAISON^® XS guarantees consistent high-quality diagnostic results but is positioned for small to medium laboratories that need a compact footprint and flexible throughout.
• Simplexa^® Direct assays are appropriate when rapid, targeted molecular results are required with minimal hands-on time, for example in acute respiratory testing.
• LIAISON PLEX^® panels are best for labs that need flexiblesyndromic, multiplex testing for respiratory and bloodstream infections
• LIAISON NES^® assays are best for urgent respiratory results needed at the point of care.
• NxTAG^® panels are best for labs that need syndromic, multiplex testing for respiratory infections
• Luminex xMAP^® platforms (MAGPIX^®, Luminex^® 200^™, and FLEXMAP 3D^® systems) serve mid- to high-plex multiplexing needs in clinical and translational settings. While, the xMAP INTELLIFLEX^® (RUO) and MAGPIX (RUO) systems provide mid- to high-plex multiplexing needs in research settings.

When choosing between platforms, laboratories should consider:

• test volume
• menu requirements
• turnaround-time expectations
• available staffing.

Diasorin materials and product specialists can help design configurations that align each lab’s workflow.

xMAP^® Technology from Luminex (part of Diasorin) is a bead-based multiplexing platform that allows simultaneous detection of multiple analytes in a single reaction.

Microparticles with distinct signatures are coated with capture molecules, enabling high-plex detection of nucleic acids or proteins on instruments such as MAGPIX^® System, Luminex^® 200^™ System, xMAP INTELLIFLEX RUO Systems, and FLEXMAP 3D^® System.

This technology allows clinical and research laboratories to:

• run large panels of targets in a single well
• conserve sample volume
• increase throughput compared with single-plex assays.

xMAP^® solutions are used across infectious diseases, immunology, research, and other specialty applications where multiplex information adds clinical value.